GBA-PD
GBA-PD is represented in the corpus as both a patient-stratification problem and a therapeutic-development problem. The pilot source range combines sample-size logic, biomarker matrices, cognitive readouts, and several GBA-pathway interventions.
Current Synthesis
The early GBA-PD section frames the program around measurable pathway biology: GCase/GBA activity, GBA protein or expression, GlcCer, GlcSph, alpha-synuclein, imaging, cognition, and progression endpoints. The same section also compares therapeutic strategies that either increase GCase function or reduce downstream lipid/pathology burden. Sources: 20240722_181748, 20240722_181752, 20240722_181756, 20240722_181800.
PR001 is handled as a gene-therapy branch with preclinical mouse, NHP biodistribution, GCase expression, lipid accumulation, alpha-synuclein, dose-selection, and clinical-trial material. Sources: 20240722_181800, 20240722_181805, 20240722_181809.
Decision Questions In The Pilot
| question | source-grounded notes |
|---|---|
| What endpoint powers a GBA-PD study? | The first pilot page includes two-group proportion scenarios for GBA activity tertile and progression to MCI/dementia. The visible examples include 30-40% target reductions and sample-size-per-arm estimates ranging from 111 to 469 depending on scenario and time window. Source: 20240722_181748. |
| Are lipids elevated enough to be useful biomarkers? | The biomarker matrix treats GlcCer and GlcSph differently across brain/CSF and GBA-PD/sPD/HC, with explicit “GAP!!” and “No data” cells. Source: 20240722_181748. |
| Should cognition be a key outcome? | The cognitive-readouts table points to MMSE, vMRI/cortical thickness, NBM neuronal loss, Lewy body pathology, and PFF mouse CA2/3 neuronal-loss associations. Source: 20240722_181748. |
| Which therapeutic logic is being compared? | The pilot contrasts ERT/GCS inhibition/GBA activation/gene therapy, including eliglustat, venglustat, ambroxol, and PR001. Sources: 20240722_181748, 20240722_181752, 20240722_181756, 20240722_181800. |
Key Source Pages
| topic | source |
|---|---|
| Biomarker matrix across GBA-PD / sPD / HC | 20240722_181748 |
| Cognitive readouts and summary section | 20240722_181748 |
| Eliglustat and ambroxol | 20240722_181748, 20240722_181752 |
| Ambroxol and venglustat | 20240722_181756 |
| Venglustat and PR001 transition | 20240722_181800 |
| PR001 preclinical package | 20240722_181805, 20240722_181809 |